Heart Failure

A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.

A study found significant drops in mean platelet volume and rises in platelet count after 6 months of SGLT2 inhibitor therapy, independent of diuretic use.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

Researchers found persistent and substantial delays between heart failure diagnosis and ATTR-CM identification.

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Medically tailored meals and produce show feasibility but no reduction in 90-day readmissions, according to one study.

Strength and aerobic training improves cardiorespiratory fitness, functional capacity, and muscle strength more than aerobic exercise alone in heart failure.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch block, despite lower costs.

Left bundle-branch pacing significantly lowered the combined risk of death or heart failure hospitalization compared with conventional biventricular pacing.

A new study finds one-third of ambulatory patients with heart failure with reduced ejection fraction overestimate their life expectancy.

High area level housing cost burden is associated with increased cardiovascular hospitalizations and emergency department use among Medicaid beneficiaries.

Incorporating triglyceride-glucose-body mass index can help better account for metabolic impacts in patients with hypertension and heart failure with mildly reduced ejection fraction.

Patients with heart failure tended to have lower treatment intensity at hospital admission, but their cardiac load improved as blood pressure treatment intensified.

An analysis shows that oral semaglutide significantly lowers the risk of heart failure (HF) outcomes in patients with type 2 diabetes and a history of HF.

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.